The sofosbuvir/ravidasvir combination treatment for hepatitis C has been shown to be safe and effective, with extremely high cure rates, according to interim results from the Phase II/III STORM-C-1 trial. "The results indicate that the sofosbuvir/ravidasvir combination is comparable to the very best hepatitis C therapies available today but it is priced affordably and could allow an alternative option in countries excluded from pharmaceutical company access programs," said the Executive Director, DNDi. DNDi conducted the STORM-C-1 open-label trial to assess the efficacy, safety, tolerance and pharmacokinetics of the drug candidate ravidasvir combined with sofosbuvir.
301 chronically infected adults were treated with the ravidasvir/sofosbuvir combination for 12 weeks for patients without cirrhosis of the liver, and for 24 weeks for those with compensated cirrhosis. In accordance with…
